Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches

Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. Insomnia is often divided into subtypes based on the prevailing symptom. Insomnia is a risk factor for developing other som...

Full description

Bibliographic Details
Main Authors: N. V. Pizova, A. V. Pizov, I. N. Solovyov
Format: Article
Language:Russian
Published: Remedium Group LLC 2022-07-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/6957
_version_ 1797841507909107712
author N. V. Pizova
A. V. Pizov
I. N. Solovyov
author_facet N. V. Pizova
A. V. Pizov
I. N. Solovyov
author_sort N. V. Pizova
collection DOAJ
description Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. Insomnia is often divided into subtypes based on the prevailing symptom. Insomnia is a risk factor for developing other somatic and mental disorders such as cerebrovascular diseases, hypertension, diabetes mellitus, depression, and causes increased healthcare costs. Given the bidirectional association of insomnia with the development of other somatic and mental diseases, the term “comorbid insomnia” may be used. The etiology and pathophysiology of insomnia involve genetic, environmental, behavioural, and physiological factors. The goals of insomnia treatment are to improve quantitative and qualitative aspects of sleep, to reduce the distress and anxiety associated with poor sleep, and to improve daytime function. Efficacious treatments for insomnia include behavioural, cognitive, and pharmacological interventions. Simple behavioural interventions may be provided in primary care facilities, but lack of training in these techniques limits their use. Among pharmacological interventions, the most evidence exists for benzodiazepine receptor agonist drugs, although on-going concerns focus on their safety as compared to modest efficacy. Different “natural” and OTC drugs are used as sleeping medications, for instance melatonin-based drugs. Behavioural treatments should be used whenever possible, and drugs should be limited to the lowest necessary dose and shortest necessary duration.
first_indexed 2024-04-09T16:31:57Z
format Article
id doaj.art-864648b09a4c4149bcac37d3c884bd7a
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:31:57Z
publishDate 2022-07-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-864648b09a4c4149bcac37d3c884bd7a2023-04-23T06:57:02ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902022-07-01011627010.21518/2079-701X-2022-16-11-62-706231Insomnia: risk factors, sex- and age-specific features, and therapeutic approachesN. V. Pizova0A. V. Pizov1I. N. Solovyov2Yaroslavl State Medical UniversityYaroslavl State Pedagogical University named after K.D. UshinskyYaroslavl State Medical UniversityInsomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. Insomnia is often divided into subtypes based on the prevailing symptom. Insomnia is a risk factor for developing other somatic and mental disorders such as cerebrovascular diseases, hypertension, diabetes mellitus, depression, and causes increased healthcare costs. Given the bidirectional association of insomnia with the development of other somatic and mental diseases, the term “comorbid insomnia” may be used. The etiology and pathophysiology of insomnia involve genetic, environmental, behavioural, and physiological factors. The goals of insomnia treatment are to improve quantitative and qualitative aspects of sleep, to reduce the distress and anxiety associated with poor sleep, and to improve daytime function. Efficacious treatments for insomnia include behavioural, cognitive, and pharmacological interventions. Simple behavioural interventions may be provided in primary care facilities, but lack of training in these techniques limits their use. Among pharmacological interventions, the most evidence exists for benzodiazepine receptor agonist drugs, although on-going concerns focus on their safety as compared to modest efficacy. Different “natural” and OTC drugs are used as sleeping medications, for instance melatonin-based drugs. Behavioural treatments should be used whenever possible, and drugs should be limited to the lowest necessary dose and shortest necessary duration.https://www.med-sovet.pro/jour/article/view/6957insomniarisk factorssex- and age-specific featurescomorbiditytherapy
spellingShingle N. V. Pizova
A. V. Pizov
I. N. Solovyov
Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches
Медицинский совет
insomnia
risk factors
sex- and age-specific features
comorbidity
therapy
title Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches
title_full Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches
title_fullStr Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches
title_full_unstemmed Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches
title_short Insomnia: risk factors, sex- and age-specific features, and therapeutic approaches
title_sort insomnia risk factors sex and age specific features and therapeutic approaches
topic insomnia
risk factors
sex- and age-specific features
comorbidity
therapy
url https://www.med-sovet.pro/jour/article/view/6957
work_keys_str_mv AT nvpizova insomniariskfactorssexandagespecificfeaturesandtherapeuticapproaches
AT avpizov insomniariskfactorssexandagespecificfeaturesandtherapeuticapproaches
AT insolovyov insomniariskfactorssexandagespecificfeaturesandtherapeuticapproaches